A specific, accurate rp-HPLC (reversed-phase high performance liquid chromatographic) method was developed for the quantification of Cabozantinib. The effective separation was achieved through reversed-phased C18 column 4.6 x 250 mm, 5µm using a mobile phase Methanol: phosphate buffer (ph. 3.00) with orthophosphoric acid (OPA) (55:45 % v/v). The flow rate of the mobile phase was found to be 0.8 mL/min. The detection was carried at a wavelength of 244 nm. The retention time of Cabozantinib was found to be 3.702 min. The correlation coefficient was found to be 0.9999. The developed method was accurately validated in the terms of accuracy, linearity range, precision, system suitability, robustness, limit of detection and limit of quantification. The details presented in this test will be useful for industrial application for determining Cabozantinib in active pharmaceutical ingredient and pharmaceutical dosage form.

No abstract

The resistant to multidrug-resistant mycobacterium tuberculosis (MDR) strains has affected to the control on tuberculosis (TB). Drugs such as isoniazid and rifampin are commonly used for the therapy in TB. In these, in the phenomenon of the production of anti-TB drugs, the maintenance of the records is one of the challenging steps. The estimated global incidences of nearly half million are witnesses for MDR/rifampicin-resistant TB. This article included the global problem of the drug resistant to TB with its lengthy, complicated, and life-threatening effects with its poor results. Recently new medicines have been developed after a long time on the treatment of TB in MDR resistance. Levofloxacin, moxifloxacin, bedaquiline, delamanid, linezolid, and other second-line medications for TB treatment include levofloxacin, moxifloxacin, bedaquiline, delamanid, linezolid, and others. In the case of MDR-TB, a variety of medications are advised. In the treatment of TB, these medications are effective anti-TB drugs. The goal of this study is to analyze MDR-TB treatment methods in light of WHO guidelines for MDR-TB care in 2021.

Anabaena PCC7120 has two annotated toxin-antitoxin systems: MazEF and HicAB. Overexpression of either of the toxins severely inhibited the growth of Escherichia coli BL21(plysS)(DE3). Of the two Anabaena toxins, MazF exhibited higher toxicity than HicA as evidenced by (i) 100-fold lower viability upon overexpression of MazF compared to HicA; (ii) complete loss of cell viability within 1 h of induction of MazF expression, as against >10 colony forming units mL in case of HicA; (iii) inability to maintain the MazF overexpressing plasmid in E. coli cells; and (iv) neutralisation of the toxin was effective at the molar ratio of 1:1.9 for MazF:MazE and 13:1 for HicA:HicB, indicating higher antitoxin requirement for neutralisation of MazF. The growth inhibitory effect of MazF was found to be higher in lag phase cultures compared to mid-logarithmic phase cultures of E. coli, while the reverse was true for HicA. The results suggest possible distinct roles for MazEF and HicAB systems of Anabaena.